Zenith Life Care Private Limited has acquired a stake in achyut healthcare through preferential allotment of equity shares, as disclosed in a regulatory filing dated March 24, 2026. The acquisition falls under the disclosure requirements of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Acquisition Details

The transaction involved the allotment of 2,00,000 equity shares to Zenith Life Care Private Limited on March 23, 2026. The acquiring company, which belongs to the promoter group, had no prior shareholding in Achyut Healthcare Limited before this acquisition.

Shareholding Structure

The preferential allotment has resulted in changes to Achyut Healthcare's equity structure. Prior to this acquisition, Zenith Life Care held no shares in the target company.

Impact on Share Capital

The preferential allotment has increased Achyut Healthcare's total equity share capital. The newly allotted shares rank pari-passu with existing equity shares and carry the same voting rights.

Regulatory Compliance

The disclosure was made by Mahendra C. Raycha, Director of Zenith Life Care Private Limited (DIN: 00577647), in compliance with Regulation 29(2) of SEBI regulations. The filing was submitted to BSE Limited, where Achyut Healthcare Limited is listed. Zenith Life Care Private Limited, incorporated in 1996 with CIN U34230GJ1996PTC031018, is based in Ahmedabad, Gujarat, and operates from the same address as Achyut Healthcare Limited at 504, Iscon Elegance, Circle P, S.G. Highway.

Achyut Healthcare Limited announced the successful completion of a preferential allotment of 58,00,000 equity shares worth ₹3,48,00,000, following Board approval on March 23, 2026. The Board meeting, held from 5:00 P.M. to 5:45 P.M. (IST), approved the allotment under SEBI regulations to promoter and non-promoter groups.

Board Meeting Outcomes and Regulatory Compliance

The Board of Directors approved the allotment of 58,00,000 equity shares of face value ₹1 each at a premium of ₹5 per share, setting the issue price at ₹6 per equity share. The company received the full consideration amount of ₹3,48,00,000 for this preferential issue conducted under SEBI (Issue of Capital & Disclosures Requirement) Regulation, 2018.

The allotment complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated November 11, 2024. The newly allotted equity shares will rank pari passu with existing equity shares in all respects, including dividend payments and voting rights.

Capital Structure Enhancement

Following the preferential allotment, the company's capital structure has been significantly enhanced:

Detailed Allottee Information

The preferential allotment was distributed among promoters, promoter group entities, and non-promoter investors with specific shareholding patterns:

Ray Remedies Private Limited Regulatory Disclosure

Ray Remedies Private Limited filed a regulatory disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, on March 24, 2026. The disclosure was submitted to BSE Limited and the Board of Directors of Achyut Healthcare Limited following the receipt of allotment through preferential basis.

The disclosure details show Ray Remedies Private Limited's shareholding increased from 77,17,500 shares (3.20%) to 79,17,500 shares (3.28%) after acquiring 2,00,000 additional shares through the preferential allotment:

The disclosure was signed by Mahendra C. Raycha, Director of Ray Remedies Private Limited (DIN: 00577647), confirming the acquisition through preferential allotment basis. The acquired equity shares carry face value of ₹1 each and rank pari-passu with existing equity shares.

Issue Structure and Compliance

The preferential issue was executed in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, read with the Companies Act, 2013 and rules made thereunder. All procedural requirements for the private placement basis allotment have been fulfilled, with comprehensive disclosure details provided as required under the regulatory framework.

The allotted equity shares carry face value of ₹1 each and rank pari-passu with existing equity shares. The company's Managing Director, Jigen Jagdishbhai Modi (DIN: 03355555), signed the regulatory filings confirming the completion of this capital-raising exercise, which strengthens the company's financial position through the infusion of ₹3.48 crores.